{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "MATTERHORN: A Randomised Controlled Trial Comparing MitraClip Transcatheter Edge-to-Edge Repair and Surgical Mitral Valve Repair in High-Risk Heart Failure Patients with Functional Mitral Regurgitation"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "The MATTERHORN trial was a multicenter, prospective, open-label, non-inferiority trial."
      },
      "Participants": {
        "score": 2,
        "evidence": "A total of 208 patients with significant FMR were randomized 1:1 to M-TEER or surgical repair. Inclusion criteria included FMR grade 3+ or 4+, LVEF \u226520%, and NYHA class \u22652."
      },
      "Intervention": {
        "score": 2,
        "evidence": "This study aimed to compare the efficacy and safety of MitraClip transcatheter edge-to-edge repair (M-TEER) versus surgical mitral valve repair."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to compare the efficacy and safety of MitraClip transcatheter edge-to-edge repair (M-TEER) versus surgical mitral valve repair in high-risk patients with heart failure and FMR."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was a composite of death, heart failure hospitalization, mitral valve re-intervention, assist device implantation, or stroke within 1 year."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "104 patients were randomized to each group."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At 1 year, the primary endpoint occurred in 16.7% of the M-TEER group and 22.5% of the surgery group (mean difference: -6 percentage points; 95% CI: -17 to 6; P < 0.001 for non-inferiority)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were lower in the M-TEER group (41.0% vs. 77.3%), with serious adverse events at 35% in M-TEER and 66% in surgery."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCTXXXXXXX."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by [Funding Source]."
      }
    },
    "total_score": 19,
    "max_score": 25
  },
  "model": "gpt-4o"
}